IL6 and ulcerative colitis: Decreased plasma levels of hs-CRP, TNF-α, plasma DA0, ET, D-lactic acid, IL-8, and IL-6 and increased CD4/CD8 ratio and CD4+ levels, enhancing the remedying impact in ulcerative colitis patients and regulating T cell frequency, in addition to reducing plasma inflammatory factors.